Retinoblastoma: An overview of modern management

Dhami, Abhinav; Bansal, Aditya; Khetan, Vikas

doi:10.3126/nepjoph.v9i1.17524

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retinoblastoma, common among children under 3, is an intraocular malignant tumour originating from the retina. The incidence of retinoblastoma accounts for 4% of all pediatric malignant tumours (Dhami et al, 2017), ranking second among them. It can affect one or both eyes and is generally fatal to young children due to its propensity for intracranial and distant metastases.…”

Section: Introductionmentioning

confidence: 99%

2D, 3D-QSAR study and docking of vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors for potential treatment of retinoblastoma

Rui

Gao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Retinoblastoma is currently the most common malignant tumor seen in newborns and children’s eyes worldwide, posing a life-threatening hazard. Chemotherapy is an integral part of retinoblastoma treatment. However, the chemotherapeutic agents used in clinics often lead to drug resistance. Thus there is a need to investigate new chemotherapy-targeted agents. VEGFR3 inhibitors are anti-tumour-growth and could be used to develop novel retinoblastoma-targeted agents.Objective: To predict drug activity, discover influencing factors and design new drugs by building 2D, 3D-QSAR models.Method: First, linear and non-linear QSAR models were built using heuristic methods and gene expression programming (GEP). The comparative molecular similarity indices analysis (COMISA) was then used to construct 3D-QSAR models through the SYBYL software. New drugs were designed by changing drug activity factors in both models, and molecular docking experiments were performed.Result: The best linear model created using HM had an R2, S2, and R2cv of 0.82, 0.02, and 0.77, respectively. For the training and test sets, the best non-linear model created using GEP had correlation coefficients of 0.83 and 0.72 with mean errors of 0.02 and 0.04. The 3D model designed using SYBYL passed external validation due to its high Q2 (0.503), R2 (0.805), and F-value (76.52), as well as its low standard error of SEE value (0.172). This demonstrates the model’s reliability and excellent predictive ability. Based on the molecular descriptors of the 2D model and the contour plots of the 3D model, we designed 100 new compounds using the best active compound 14 as a template. We performed activity prediction and molecular docking experiments on them, in which compound 14.d performed best regarding combined drug activity and docking ability.Conclusion: The non-linear model created using GEP was more stable and had a more substantial predictive power than the linear model built using the heuristic technique (HM). The compound 14.d designed in this experiment has the potential for anti-retinoblastoma treatment, which provides new design ideas and directions for retinoblastoma-targeted drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

2D, 3D-QSAR study and docking of vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors for potential treatment of retinoblastoma

Rui

Gao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…At the beginning, the tumour grows on the retina. During this stage, the usual treatments are cryotherapy or surgery complemented by localized chemotherapy, depending on the tumour size . At this point, if not treated in time, the tumour detaches from the retina and starts floating in the vitreous body.…”

Section: Introductionmentioning

confidence: 99%

Laser‐induced plasmon‐mediated treatment of retinoblastoma in viscous vitreous phantom

Darviot

Hardy

Meunier

2019

Journal of Biophotonics

View full text Add to dashboard Cite

Retinoblastoma (RB) is a rare form of cancer of the retina most prevalent in young children. We successfully show that laser-induced cell disruption, mediated by gold plasmonic nanoparticle (NP), is a potential and efficient therapy to kill the cancerous cells. The proof of concept is demonstrated in vitro on cultured Y79 RB cancer cells with a nanosecond laser at 527 nm, for both attached cells at the bottom of a Petri dish and for floating, clustered cells in a viscous vitreous phantom comprised of hyaluronan. We report a cellular death of 82% after irradiation in classic culture medium and a cellular death of 98% in vitreous phantom, for similar number of NPs in each sample. It is found that the NPs efficiently penetrate the floating Y79 clusters cells in the vitreous phantom, leading to a cellular death of over 85% even within the centre of the aggregates. The proposed treatment technique is based on a similar nanosecond laser used to eliminate floaters in the vitreous, but with much lower (100-1000 times) fluences of 20 J cm −2 . K E Y W O R D Scancer, gold nanoparticles, retinoblastoma, vitreous phantom

show abstract

Progress in the Treatment of Retinoblastoma

杨¹

2019

WJCR

View full text Add to dashboard Cite

Retinoblastoma: An overview of modern management

Abstract: Retinoblastoma (RB) is an embryonic tumor originating from the retinal cells. RB is the most common intraocular cancer of childhood and accounts for 4% of all pediatric malignancies.

Cited by 3 publications

References 12 publications

2D, 3D-QSAR study and docking of vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors for potential treatment of retinoblastoma

2D, 3D-QSAR study and docking of vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors for potential treatment of retinoblastoma

Laser‐induced plasmon‐mediated treatment of retinoblastoma in viscous vitreous phantom

Progress in the Treatment of Retinoblastoma

Contact Info

Product

Resources

About